Literature DB >> 9177661

Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home.

D Lieberman1, D Lieberman1, F Schlaeffer, A Porath.   

Abstract

OBJECTIVE: to characterize the background, aetiology, clinical course and outcome of community-acquired pneumonia (CAP) in elderly compared with younger patients.
DESIGN: a 1 year prospective study.
SETTING: a university hospital in southern Israel. PARTICIPANTS: ninety-one patients over 65 years who were hospitalized from their homes with CAP. These patients were compared with a reference group of 54 CAP patients, aged 55-64 years. MEASUREMENTS: an intensive work-up (primarily serological) to identify the aetiological causes of CAP. The age groups were compared in terms of variables related to CAP.
RESULTS: the proportion with pneumococcal infection, the most common aetiology for CAP, increased from 29.6% in the 55-64-year group through 45.6% in the 65-74-year group; up to 57.8% in the 75+ group (P = 0.019). Chlamydia pneumoniae was identified as the aetiological agent in 26.4% of elderly patients. Mortality in patients > or = 75 years was 20% and was significantly higher than in the two younger age groups (P = 0.019). The leucocyte count was significantly higher among the elderly group (P = 0.013) and the serum urea concentration was higher in patients 75 years and older (P = 0.025). The proportion of patients treated with antibiotics before admission decreased with increasing age (P = 0.026).
CONCLUSIONS: CAP has more serious clinical and abnormal laboratory features in the elderly than younger patients, particularly in those over 75. In independent elderly people, the pneumococcus is the most common causative agent for CAP but other agents, particularly C. pneumoniae, are common. Initial antibiotic treatment for these patients should therefore include a macrolide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177661     DOI: 10.1093/ageing/26.2.69

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  10 in total

1.  Pneumococcal Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

2.  Community acquired pneumonia in elderly people. Addition of erythromycin is not currently justified.

Authors:  M Woodhead
Journal:  BMJ       Date:  1998-11-28

3.  Community acquired pneumonia in elderly people. Current British guidelines need revision.

Authors:  S J Wort; T R Rogers
Journal:  BMJ       Date:  1998-06-06

Review 4.  Community-acquired pneumonia in the elderly: a practical guide to treatment.

Authors:  D Lieberman; D Lieberman
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

Review 5.  Pneumococcal vaccination and revaccination of older adults.

Authors:  Andrew S Artz; William B Ershler; Dan L Longo
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

6.  Evolutionary conservation of infection-induced cell death inhibition among Chlamydiales.

Authors:  Karthika Karunakaran; Adrian Mehlitz; Thomas Rudel
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

Review 7.  [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features].

Authors:  F Philippart
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

Review 8.  Epidemiology and etiology of community-acquired pneumonia.

Authors:  Lionel A Mandell
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

9.  Respiratory viruses in adults with community-acquired pneumonia.

Authors:  David Lieberman; Avi Shimoni; Yonat Shemer-Avni; Ayelet Keren-Naos; Rachel Shtainberg; Devora Lieberman
Journal:  Chest       Date:  2010-04-02       Impact factor: 9.410

10.  Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia.

Authors:  Young Ae Kang; Sung-Youn Kwon; Ho Il Yoon; Jae Ho Lee; Choon-Taek Lee
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.